Skip to content

Author

F. Pietrantonio

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials

Background In resected liver-limited metastatic colorectal cancer (LL-mCRC), disease-free survival (DFS) and postsurgical overall survival (psOS) have been found to be weakly related in heterogeneous retrospective series, challenging the role of DFS as a surrogate biomarker of psOS. Additionally, it remains unclear whe...

M. Germani, A. Taravella, D. Rossini et al. · 0 citations
Open access Oct 2026

The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study.

BACKGROUND Adjuvant chemotherapy (ACT) indication in stage II colorectal cancer (CRC) remains challenging, as clinical, pathological, and ctDNA inadequately predict benefit. Immune infiltration correlates with outcome, yet transcriptional signatures have not been systematically evaluated in prospective trial cohorts. W...

A. Puccini, L. Ferrando, G. Frige' et al. · 0 citations
Review Oct 2026

Optimizing neoadjuvant immunotherapy in rectal cancer.

The integration of immune checkpoint inhibitors (ICIs) into neoadjuvant strategies is increasingly being studied in locally advanced rectal cancer (LARC), to improve complete response (CR), organ preservation, and potentially overall survival (OS). However, the clinical impact of conventional PD-1 blockade still remain...

G. Pennoni, G. Rebecchi, Miao-Miao Gou et al. · 0 citations
Open access Sep 2026

Microbiome alterations in mismatch-repair deficient metastatic colorectal cancer patients

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Many efforts have been made to stratify CRC cases, from investigating the genomic characteristics of the tumor to – more recently – considering the gut microbiome. Differences in the composition of the gut microbiome occur along...

Gianmarco Piccinno, Paolo Manghi, Luca Lazzari et al. · 0 citations
Open access Sep 2026

Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial

Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...

Davide Ciardiello, G. Martini, L. Boscolo Bielo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.